Intravenous Immunomodulatory Nanoparticle Treatment for Traumatic Brain Injury.

ABSTRACT:

Objective

There are currently no definitive disease-modifying therapies for traumatic brain injury (TBI). In this study, we present a strong therapeutic candidate for TBI, immunomodulatory nanoparticles (IMPs), which ablate a specific subset of hematogenous monocytes (hMos). We hypothesized that prevention of infiltration of these cells into brain acutely after TBI would attenuate secondary damage and preserve anatomic and neurologic function.

Methods

IMPs, composed of US Food and Drug Administration-approved 500nm carboxylated-poly(lactic-co-glycolic) acid, were infused intravenously into wild-type C57BL/6 mice following 2 different models of experimental TBI, controlled cortical impact (CCI), and closed head injury (CHI).

Results

IMP administration resulted in remar

SUBMITTER: Sharma S 

PROVIDER: S-EPMC7296512 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature